2010 American Heart Association

triphosphate in the treatment of paroxysmal supraventricular
tachycardia]. Arq Bras Cardiol. 1996;66:55–57.
404. Rankin AC, Rae AP, Oldroyd KG, Cobbe SM. Verapamil or adenosine
for the immediate treatment of supraventricular tachycardia. Q J Med.
1990;74:203–208.
405. Joshi PP, Deshmukh PK, Salkar RG. Efficacy of intravenous magnesium
sulphate in supraventricular tachyarrhythmias. J Assoc Physicians India.
1995;43:529–531.
406. Gupta A, Naik A, Vora A, Lokhandwala Y. Comparison of efficacy of
intravenous diltiazem and esmolol in terminating supraventricular
tachycardia. J Assoc Physicians India. 1999;47:969–972.
407. Boudonas G, Lefkos N, Efthymiadis AP, Styliadis IG, Tsapas G. Intravenous
administration of diltiazem in the treatment of supraventricular
tachyarrhythmias. Acta Cardiol. 1995;50:125–134.
408. Marill KA, Wolfram S, Desouza IS, Nishijima DK, Kay D, Setnik GS,
Stair TO, Ellinor PT. Adenosine for wide-complex tachycardia: efficacy
and safety. Crit Care Med. 2009;37:2512–2518.
409. Domanovits H, Laske H, Stark G, Sterz F, Schmidinger H, Schreiber W,
Mullner M, Laggner AN. Adenosine for the management of patients
with tachycardias—a new protocol. Eur Heart J. 1994;15:589–593.
410. Ilkhanipour K, Berrol R, Yealy DM. Therapeutic and diagnostic efficacy
of adenosine in wide-complex tachycardia. Ann Emerg Med. 1993;22:
1360–1364.
411. Rankin AC, Oldroyd KG, Chong E, Rae AP, Cobbe SM. Value and
limitations of adenosine in the diagnosis and treatment of narrow and
broad complex tachycardias. Br Heart J. 1989;62:195–203.
412. Wilber DJ, Baerman J, Olshansky B, Kall J, Kopp D. Adenosinesensitive
ventricular tachycardia. Clinical characteristics and response to
catheter ablation. Circulation. 1993;87:126–134.
413. Armengol RE, Graff J, Baerman JM, Swiryn S. Lack of effectiveness of
lidocaine for sustained, wide QRS complex tachycardia. Ann Emerg
Med. 1989;18:254–257.
414. Exner DV, Muzyka T, Gillis AM. Proarrhythmia in patients with the
Wolff-Parkinson-White syndrome after standard doses of intravenous
adenosine. Ann Intern Med. 1995;122:351–352.
415. Gupta AK, Shah CP, Maheshwari A, Thakur RK, Hayes OW,
Lokhandwala YY. Adenosine induced ventricular fibrillation in Wolff-
Parkinson-White syndrome. Pacing Clin Electrophysiol. 2002;25:
477–480.
416. Shah CP, Gupta AK, Thakur RK, Hayes OW, Mehrotra A, Lokhandwala
YY. Adenosine-induced ventricular fibrillation. Indian Heart J. 2001;
53:208–210.
417. Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Case report:
adenosine induced ventricular fibrillation in a patient with stable ventricular
tachycardia. J Interv Card Electrophysiol. 2001;5:71–74.
418. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME.
Hazards of intravenous verapamil for sustained ventricular tachycardia.
Am J Cardiol. 1987;59:1107–1110.
419. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos
MA, Wellens HJ. Comparison of procainamide and lidocaine in terminating
sustained monomorphic ventricular tachycardia. Am J Cardiol.
1996;78:43–46.
420. Ho DS, Zecchin RP, Richards DA, Uther JB, Ross DL. Double-blind
trial of lignocaine versus sotalol for acute termination of spontaneous
sustained ventricular tachycardia. Lancet. 1994;344:18–23.
421. Ho DSW, Zecchin RP, Cooper MJ, Richards DAB, Uther JB, Ross DL.
Rapid intravenous infusion of d-1 sotalol: time to onset of effects on
ventricular refractoriness, and safety. Eur Heart J. 1995;16:81–86.
422. Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, Ruskin JN.
Amiodarone is poorly effective for the acute termination of ventricular
tachycardia. Ann Emerg Med. 2006;47:217–224.
423. Schutzenberger W, Leisch F, Kerschner K, Harringer W, Herbinger W.
Clinical efficacy of intravenous amiodarone in the short term treatment
of recurrent sustained ventricular tachycardia and ventricular fibrillation.
Br Heart J. 1989;62:367–371.
424. Tomlinson DR, Cherian P, Betts TR, Bashir Y. Intravenous amiodarone
for the pharmacological termination of haemodynamically-tolerated sustained
ventricular tachycardia: is bolus dose amiodarone an appropriate
first-line treatment? Emerg Med J. 2008;25:15–18.
425. Nasir N Jr, Taylor A, Doyle TK, Pacifico A. Evaluation of intravenous
lidocaine for the termination of sustained monomorphic ventricular
Neumar et al Part 8: Adult Advanced Cardiovascular Life Support S767
tachycardia in patients with coronary artery disease with or without
healed myocardial infarction. Am J Cardiol. 1994;74:1183–1186.
426. Marill KA, Greenberg GM, Kay D, Nelson BK. Analysis of the
treatment of spontaneous sustained stable ventricular tachycardia. Acad
Emerg Med. 1997;4:1122–1128.
427. Koster RW, Dunning AJ. Intramuscular lidocaine for prevention of
lethal arrhythmias in the prehospitalization phase of acute myocardial
infarction. N Engl J Med. 1985;313:1105–1110.
428. Roth A, Malov N, Bloch Y, Schlesinger Z, Laniado S, Kaplinski E.
Usefulness of self-administration of intramuscular lidocaine in the prehospital
setting for ventricular tachyarrhythmias unassociated with acute
myocardial infarction (The “SHAHAL” experience in Israel). Am J
Cardiol. 1997;79:611–614.
429. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen
KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB,
Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams
CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R,
Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ,
Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K,
Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL. ACC/
AHA/ESC 2006 Guidelines for the Management of Patients with Atrial
Fibrillation: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines (Writing
Committee to Revise the 2001 Guidelines for the Management of
Patients With Atrial Fibrillation): developed in collaboration with the
European Heart Rhythm Association and the Heart Rhythm Society.
Circulation. 2006;114:e257–e354.
430. Sticherling C, Tada H, Hsu W, Bares AC, Oral H, Pelosi F, Knight BP,
Strickberger SA, Morady F. Effects of diltiazem and esmolol on cycle
length and spontaneous conversion of atrial fibrillation. J Cardiovasc
Pharmacol Ther. 2002;7:81–88.
431. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous
magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. Int
J Cardiol. 2001;79:287–291.
432. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial
fibrillation and flutter: intravenous diltiazem versus intravenous digoxin.
Ann Emerg Med. 1997;29:135–140.
433. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is
superior to intravenous amiodarone or digoxin for achieving ventricular
rate control in patients with acute uncomplicated atrial fibrillation. Crit
Care Med. 2009;37:2174–2179, quiz 2180.
434. Intravenous digoxin in acute atrial fibrillation. Results of a randomized,
placebo-controlled multicentre trial in 239 patients. The Digitalis in
Acute Atrial Fibrillation (DAAF) Trial Group. Eur Heart J. 1997;18:
649–654.
435. Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, Vertongen
P, Bergez B, Vandekerckhove Y. Conversion of atrial fibrillation to
sinus rhythm and rate control by digoxin in comparison to placebo. Eur
Heart J. 1997;18:643–648.
436. Wattanasuwan N, Khan IA, Mehta NJ, Arora P, Singh N, Vasavada BC,
Sacchi TJ. Acute ventricular rate control in atrial fibrillation: IV combination
of diltiazem and digoxin vs IV diltiazem alone. Chest. 2001;
119:502–506.
437. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D,
Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial
fibrillation: results of a randomized, controlled study. J Am Coll Cardiol.
1996;27:1079–1082.
438. Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross
DL, Cooper MJ. Rapid loading of sotalol or amiodarone for management
of recent onset symptomatic atrial fibrillation: a randomized,
digoxin-controlled trial. Am Heart J. 2004;147:E3.
439. Keren A, Tzivoni D, Gavish D, Levi J, Gottlieb S, Benhorin J, Stern S.
Etiology, warning signs and therapy of torsade de pointes: a study of 10
patients. Circulation. 1981;64:1167–1174.
440. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular
tachycardia: clinical characterization, therapy, and the QT interval.
Circulation. 1986;74:340–349.
KEY WORDS: arrhythmia � cardiac arrest � drugs � ventricular arrhythmia
� ventricular fibrillation
Downloaded from
circ.ahajournals.org at NATIONAL TAIWAN UNIV on October 18, 2010